Date: 2014-10-08
Type of information: Construction of a production plant
Compound:
Company: CSL (Australia)
Therapeutic area:
Type agreement: extension of a production plant
Action mechanism:
Disease:
Details: * On October 8, 2014, CSL announced a $210 million expansion of its CSL Behring manufacturing site in Broadmeadows (Melbourne) to help meet growing demand for its global critical care therapy, albumin. The investment will fund a new manufacturing facility on the site, creating 200 jobs during construction and a further 190 highly skilled manufacturing jobs once the plant is fully operational. CSL’s global albumin product is currently manufactured by CSL Behring’s US, German and Swiss facilities using plasma collected by CSL Plasma’s international collection centres. The new facility at Broadmeadows will become an integral part of this global supply chain and will have the capacity to make a significant contribution to CSL’s total global albumin output. As part of CSL’s ongoing expansion strategy, the Company chose to add albumin manufacturing capacity at Broadmeadows following a competitive review of all CSL Behring sites within its global network. A strategic contribution from the Victorian Government was instrumental to the success of the Broadmeadows bid. The Broadmeadows site currently employs 650 highly skilled workers. In 2012 CSL integrated the Broadmeadows site with the CSL Behring global network. It recently opened on the site a new biotech facility for novel product development and will soon open an adjacent plant to manufacture CSL’s global immune disorder therapy for export markets. These facilities represent an investment of more than $250m and were supported by previous strategic grants from the Victorian and Federal governments. The new facility will comprise two manufacturing modules. Construction of the first module will begin in the next several weeks and will take about 4 years to complete. At full capacity, CSL estimates the annual commercial value of the albumin to be exported from the facility could be approximately $US600m.
Financial terms:
Latest news:
